Arcus Biosciences, Inc.

This study is testing if adding a new drug called casdatifan to an existing cancer drug (cabozantinib) works better than cabozantinib alone for people with advanced kidney cancer. It's for patients whose cancer has continued to grow despite previous immunotherapy treatment. The m…

This is the first study in people to test a new drug called AB521 (casdatifan). The main goal is to find safe doses and see how the body processes the drug. It will be tested alone and in combinations for people with advanced kidney cancer and other solid tumors that have not res…

This early-stage study aims to understand how the body processes and eliminates the experimental drug quemliclustat. Eight healthy adult male volunteers will receive a single dose containing a tiny, safe amount of radioactive tracer. Researchers will then measure how much of the …